MYRIAD GENETICS INC
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for
Condensed Consolidated Statements of Cash Flows (unaudited)
| Nine months ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(358.0) | $(84.8) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 41.1 | 46.4 |
| Non-cash lease expense | 6.6 | 6.7 |
| Stock-based compensation expense | 32.4 | 38.9 |
| Deferred income taxes | — | (3.0) |
| Unrecognized tax benefits | (31.5) | 1.2 |
| Impairment of goodwill and long-lived assets | 316.7 | 13.6 |
| Gain on termination of lease | — | (3.1) |
| Gain on acquisition | — | (2.2) |
| Other non-cash adjustments | 1.6 | 1.2 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (3.1) | (4.6) |
| Trade accounts receivable | 3.6 | (12.7) |
| Inventory | (4.1) | (4.9) |
| Prepaid taxes | 2.6 | (0.1) |
| Other assets | 1.3 | (0.2) |
| Accounts payable | 2.8 | 5.8 |
| Accrued liabilities | (20.8) | (13.5) |
| Net cash used in operating activities | (8.8) | (15.3) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures | (10.9) | (15.4) |
| Capitalization of intangible assets | (10.5) | (8.4) |
| Proceeds from the sale of businesses, net of cash sold | — | 8.8 |
| Proceeds from maturities and sales of marketable investment securities | — | 9.0 |
| Net cash used in investing activities | (21.4) | (6.0) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from common stock issued under stock-based compensation plans | 2.7 | 3.0 |
| Payment of tax withheld for common stock issued under stock-based compensation plans | (6.1) | (12.2) |
| Proceeds from revolving credit facility | 40.0 | 100.0 |
| Repayment of revolving credit facility | (80.5) | (100.0) |
| Proceeds from the issuance of secured long-term credit facility | 125.0 | — |
| Fees associated with the issuance of secured long-term credit facility | (8.4) | — |
| Payment on finance leases | (0.3) | (0.3) |
| Net cash provided by (used in) financing activities | 72.4 | (9.5) |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 0.7 | (0.3) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 42.9 | (31.1) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 111.9 | 140.9 |
| Cash, cash equivalents, and restricted cash at end of the period | $154.8 | $109.8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.